biostudies-literatureKang XNCI NIH HHSNational Institutes of HealthLeukemia and Lymphoma Society30https://www.ebi.ac.uk/biostudies/studies/S-EPMC5828341biostudies-literatureUnknown11(1)<h4>Background</h4>We recently identified the human leukocyte immunoglobulin-like receptor B2 (LILRB2) and its mouse ortholog-paired Ig-like receptor (PirB) as receptors for several angiopoietin-like proteins (Angptls). We also demonstrated that PirB is important for the development of acute myeloid leukemia (AML), but exactly how an inhibitory receptor such as PirB can support cancer development is intriguing.<h4>Results</h4>Here, we showed that the activation of Ca (2+)/calmodulin-dependent protein kinases (CAMKs) is coupled with PirB signaling in AML cells. High expression of CAMKs is associated with a poor overall survival probability in patients with AML. Knockdown of CAMKI or CAMKIV decreased human acute leukemia development in vitro and in vivo. Mouse AML cells that are defective inJournal of hematology & oncologyCAMKs support development of acute myeloid leukemia.PMC5828341R01 CA1722681R01CA1722681024-14Zhang CCKang XMuschen MHuang JWang CLu ZChen HWu GWang LWang HYZhao MGeng HChen ZChen XCui CfalseCAMKs support development of acute myeloid leukemia.<h4>Background</h4>We recently identified the human leukocyte immunoglobulin-like receptor B2 (LILRB2) and its mouse ortholog-paired Ig-like receptor (PirB) as receptors for several angiopoietin-like proteins (Angptls). We also demonstrated that PirB is important for the development of acute myeloid leukemia (AML), but exactly how an inhibitory receptor such as PirB can support cancer development is intriguing.<h4>Results</h4>Here, we showed that the activation of Ca (2+)/calmodulin-dependent protein kinases (CAMKs) is coupled with PirB signaling in AML cells. High expression of CAMKs is associated with a poor overall survival probability in patients with AML. Knockdown of CAMKI or CAMKIV decreased human acute leukemia development in vitro and in vivo. Mouse AML cells that are defective in2018-01-01T00:00:00Z2018 Feb2025-04-21T20:09:24.019Z2019-03-26T23:04:27ZS-EPMC58283412948258210.1186/s13045-018-0574-8